Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cytavis BioPharma
Hamburg, Hamburg, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
Aviscumine (recombinant viscumine/mistletoe lectin) showed an excellent safety profile in phase I/II trials (no life-threatening or serious adverse events) and demonstrated effectiveness in metastatic melanoma (Phase II), with preliminary evidence of immunostimulatory and cytotoxic activity in multiple solid tumors.[2][3][5][7]
- Therapeutic areas
- Oncology
- Modalities
- Recombinant proteinBiologic
- Industry
- Biotech
02
Partnerships
University of Texas M. D. Anderson Cancer CenterUniversity of Tübingen
Beyond the preview
Go deeper on Cytavis BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytavis BioPharma.